Cogent Biosciences, Inc. announced the completion of a $230 million public offering of 1.625% Convertible Senior Notes due in 2031 on November 18, 2025, including an additional $30 million from underwriters' option. The notes will mature on November 15, 2031, and will have an initial conversion price of approximately $44.95 per share, allowing conversion under certain conditions.